Iocure

Iocure is an early-stage pharmaceutical startup focused on developing, formulating, and launching low-risk therapies for respiratory pathogens, including COVID-19 and the common cold. Founded in 2020 by physician Daniel Farb, MD, the company's technology centers on the use of iodine compounds, specifically povidone-iodine (PVP-I) formulations, designed to safely and effectively target viruses in the nasal passages and upper respiratory tract. Iocure's proprietary approach aims to deliver these therapeutic agents in a manner that minimizes local irritation and toxicity while maximizing antiviral efficacy. The company has pursued patent protection for its iodine-based formulations and has sought partnerships and funding to advance its candidates into clinical development.